PRELUDE THERAPEUTICS I

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

31 май 2023 07:30:00 Источник Nasdaq GlobeNewswire

Prelude Therapeutics Announces Pricing of Public Offering

18 май 2023 06:00:00 Источник Nasdaq GlobeNewswire

Prelude Therapeutics Announces Launch of Proposed Public Offering

17 май 2023 15:08:22 Источник Nasdaq GlobeNewswire

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

08 май 2023 07:30:00 Источник Nasdaq GlobeNewswire

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

27 апр 2023 07:30:00 Источник Nasdaq GlobeNewswire

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

11 апр 2023 07:30:00 Источник Nasdaq GlobeNewswire

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

15 мар 2023 07:30:00 Источник Nasdaq GlobeNewswire

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

15 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

01 мар 2023 07:30:00 Источник Nasdaq GlobeNewswire

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

09 фев 2023 08:05:00 Источник Nasdaq GlobeNewswire

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

14 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

18 окт 2022 07:00:01 Источник Nasdaq GlobeNewswire

Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences

06 сен 2022 07:00:02 Источник Nasdaq GlobeNewswire

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

09 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

10 май 2022 07:00:02 Источник Nasdaq GlobeNewswire

Prelude Therapeutics Reports Full Year 2021 Financial Results

16 мар 2022 06:30:00 Источник Nasdaq GlobeNewswire

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

11 мар 2022 07:00:00 Источник Nasdaq GlobeNewswire

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

09 мар 2022 07:05:00 Источник Nasdaq GlobeNewswire

Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

09 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 фев 2022 06:00:00 Источник Nasdaq GlobeNewswire